Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Long-term sustained delivery of 3'-azido-2',3'-dideoxythymidine in vivo by means of HA and TCP delivery devices.
Biomed Sci Instrum. 2000;36:343-8. Unique Identifier : AIDSLINE MED/20294166 Benghuzzi H; Department of Health Sciences, School of Health Related; Professions, University of Mississippi Medical Center, Jackson,; USA.
Abstract:
This study will attempt to determine the amount of circulating drug, when provided at sustained levels over an extended period of time, which provides efficacy and reduces the toxic side effects seen with the use of AZT in vivo. Two ceramic delivery systems were selected for this investigation namely tricalcium-phosphate (TCP) and hydroxyapatite (HA) ceramic implants. Three different dosages were selected (60, 90, 180 mg AZT). A total of 105 rats were used in this study and they were further divided into seven equal groups (n = 15 per group, 250-300 gm BW). Rats in groups I, II and III were implanted with TCP ceramic capsules containing 30, 60, and 90 mg AZT powder, respectively. Each rat in groups IV, V, and VI were implanted with HA capsules containing 30, 60, and 90 mg AZT powder, respectively. Rats in group VII were unimplanted and served as controls. The standard aseptic surgical techniques were performed in this investigation. Rats were anesthetized with a mixture of Zylazine/Ketamine, and their hind limbs shaved and scrubbed with providone iodine. The sterilized ceramics (gas/24 hours) were inserted under the skin using standard surgical techniques. After implantation, the site was sealed with wound clips, and the animals were injected with 0.1 ml of 200,000 units of Penicillin. At the end of 2, 4, and 6 weeks after implantation, five rats from each group were euthanized and the ceramic capsules, reproductive, and vital organs were removed and examined by following standard laboratory protocols. Results obtained from this study revealed that the rates of AZT released from TCP ceramic implants (30 mg = 2.38 +/- 0.23 ng/ml, 60 = 4.64 +/- 1.03 ng/ml, and 90 mg = 11.92 +/- 2.36 ng/ml serum AZT) were significantly higher than the rates of AZT released from HA ceramic implants (30 mg = 0.84 +/- 0.05 ng/ml, 60 = 2.40 +/- 0.83 ng/ml, and 90 mg = 6.41 +/- 1.24 ng/ml serum AZT). Data obtained from this investigation suggest that: (I) TCP and HA ceramic implants can be used effectively to deliver AZT in amounts capable of eliciting physiological responses in vivo, and (II) large fluctuations of AZT concentrations in the blood stream and tissues due to the conventional routes of administration could be eliminated by using ceramic sustained delivery system.
Keywords: JOURNAL ARTICLE Animal Anti-HIV Agents/*ADMINISTRATION & DOSAGE/PHARMACOKINETICS Calcium Phosphates Ceramics *Drug Delivery Systems Drug Implants Durapatite Rats Zidovudine/*ADMINISTRATION & DOSAGE/PHARMACOKINETICS
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from
Elton John AIDS Foundation,
the National Library of Medicine,
and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
